Looking forward, for the full year, the Company expects between 10% – 15% revenue growth year-over-year, driven by continued revenue growth through our e-commerce business as well as established partnerships, and assumes upside from opportunities with new partnerships, channels, and products. The Company projects that gross margin will improve slightly year-over-year. Moreover, selling and marketing expense will increase in absolute dollars but remain stable as a percentage of net sales, as the Company continues to make focused investments to drive brand awareness and support new market launches, while maintaining efficiency. The Company plans to continue to invest in research and development to drive future innovation and expects general and administrative expense to be down $1.5 million year over year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDXC:
- ChromaDex Corporation (CDXC) Q2 Earnings Cheat Sheet
- ChromaDex launches Niagen+ NAD+ Test Kit available exclusively to HCPs
- ChromaDex announces appointment of Carlos Lopez as General Counsel
- ChromaDex to debut pharmaceutical-grade Niagen at clinics in August
- ChromaDex to be included in Russell 2000 Index
Questions or Comments about the article? Write to editor@tipranks.com